Program Members

Executive Director

Naoto Ueno, MD, PhD, FACPNaoto Ueno, MD, PhD, FACP

Dr. Ueno's work focuses upon:

  • Elucidating the role of EMT, metastasis, and cancer stem cells in IBC
  • Development of novel clinical trials for IBC
  • Elucidating the role of ERK pathway in IBC
  • Conducting whole genome and cDNA microarray analysis of IBC


Deputy Director and Member, Executive Committee

Wendy Woodward, MD, PhDWendy Woodward, MD, PhD

Dr. Woodward's work focuses upon:

  • Providing conformal radiation therapy for patients with IBC
  • Characterizing radiation resistance in IBC stem cells
  • Examining mechanisms of sensitizing IBC to radiation including targeting stem cell signaling pathways, signaling, and epithelial mesenchymal transition (EMT) in IBC cells and tumor models

Read about Dr. Woodward's Lab.


Director, Clinical Research

Vicente Valero, MD, FACPVicente Valero, MD, FACP

Dr. Valero's work focuses upon:

  • Investigating breast neoplasms, unusual histologies, new drug development, and clinical trials targeting health disparities
  • Treating inflammatory breast cancer utilizing new biological agents, gene profiling, and clinical trials



Member, Executive Committee

James Reuben, PhDJames Reuben, PhD

Dr. Reuben's work focuses upon:

  • Elucidating the role of EMT and cancer stem cells in IBC
  • Characterizing the role of microRNA in IBC
  • Developing new molecular-based technologies to detect circulating tumor cells (CTC) while evaluating stem cell properties in CTCs
  • Providing laboratory support for monitoring and evaluating IBC patients on clinical trials


Special Advisor

Thomas Buchholz, MDThomas Buchholz, MD

Dr. Buchholz's work focuses upon:

  • Defining optimal radiation treatment strategies
  • Elucidating molecular and genetic factors that determine IBC development and treatment response



Core Leader

Anthony Lucci, MDAnthony Lucci, MD

Dr. Lucci's work focuses upon:

  • Investigating targetable networks in the aggressive sub-populations of IBC cells and metabolism in IBC
  • Developing new laboratory-based assays to evaluate novel therapies against IBC
  • Evaluating novel therapies in xenograft mouse models of IBC
  • Determining the DTC and CTC status of IBC patients
  • Maintaining a database of test results and outcomes of IBC patients
  • Investigating the molecular characteristics of DTCs and CTCs from IBC patients

Core Leader

Savitri Krishnamurthy, MDSavitri Krishnamurthy, MD

Dr. Krishnamurthy's work focuses upon:

  • Investigating molecular and biologic markers in IBC
  • Providing laboratory support for through tissue specimen preparation, interpretation, and ancillary techniques, including immunohistochemistry and in situ hybridization



Core Leader

Huong Le-Petross, MDHuong Le-Petross, MD

Dr. Le-Petross's work focuses upon:

  • Evaluating the utility of Contrast-Enhanced Magnetic Resonance Imaging and Advanced MR Imaging Techniques, such as MR Spectroscopy and MR Diffusion-Weighted Imaging, in IBC patients at the initial staging and for therapy response assessment



Core Leader

Randa El_Zein, MD, PhDRanda El_Zein, MD, PhD

Dr. El Zein's work focuses upon:

  • Exploring the epidemiological factors associated with IBC
  • Determining the role of viruses and IBC
  • Collaborating with international teams comparing IBC in the US with other high risk areas




Gildy Babiera, MDGildy Babiera, MD

Dr. Babiera's work focuses upon:

  • Resection of primary tumor for Stage IV inflammatory breast cancer (IBC)
  • Extent of surgical resection after neoadjuvant chemotherapy




James Bankson, PhDJames Bankson, PhD

Dr. Bankson's work focuses upon:

  • Preclinical MR imaging (MRI) of small animals
  • Quantitation and parametric derivation from preclinical MRI (e.g., via DCE) and MR spectroscopy (MRS)




Yun Gong, MDYun Gong, MD

Dr. Gong's work focuses upon:

  • Providing tissue banking from IBC patients who are diagnosed and/or treated at MD Anderson
  • Performing pathologic (morphologic and immunohistochemical) evaluation on IBC-related projects





Bora Lim, MD

Dr. Lim's work focuses upon:

  • Development of synthetic apoptosis/mitotic catastrophe strategy in IBC
  • Development of novel biomarker of investigate and monitor the response to the treatment in IBC
  • Elucidating microenvironment and metabolism of IBC, and develop targeting strategy



Laszlo Radvanyi, PhDLaszlo Radvanyi, PhD







Khandan Keyomarsi, PhDKhandan Keyomarsi, PhD







Elizabeth A Mittendorf, MDElizabeth A Mittendorf, MD

Dr. Mittendorf's work focuses upon:

  • Studying immunologic aspects of the breast tumor microenvironment
  • Conducting clinical trials evaluating breast cancer immunotherapy
  • Providing surgical care to patients diagnosed with breast cancer.




Bedrich Eckhardt, PhDBedrich Eckhardt, PhD

Dr. Eckhardt's work focuses upon:

  • Utilizing multiple discovery platforms including; forward genetic screens (shRNA), phage-based peptide display, and ChIP-Seq to identify novel molecular interactions that occur during the development of IBC and metastatic breast cancer
  • Elucidating the role of BMP-SMAD signaling in preclinical models of spontaneous breast cancer metastasis




Tamer Fouad, MD, PhDTamer M. Fouad, MD, PhD

Dr. Fouad's work focuses upon:

  • Identifying predictive and prognostic models to facilitate treatment selection in IBC and metastatic breast cancer
  • Development of gene signatures to predict treatment efficacy in endocrine resistant ER+ breast cancers
  • Exploring the epidemiological factors associated with IBC
  • Comparing IBC populations in the US and areas of high risk such as North Africa


Sarah M. DeSnyder, MDSarah M. DeSnyder, MD

Dr. DeSnyder's work focuses upon:

  • Assessing accuracy of pre-operative imaging in identifying axillary metastasis and assessing accuracy of sentinel lymph node biopsy in patients with IBC
  • Identifying patients with IBC who may benefit from less aggressive surgical treatment after response to systemic therapy




Mariana Chavez Mac Gregor, MDMariana Chavez Mac Gregor, MD

Dr. Mac Gregor's work focuses upon:

  • Outcomes and disparities research
  • Enderstanding the long -term effects of therapy and evaluating quality of care at a population level
  • Comprehensive and compassionate treatment of breast cancer patients with an interest in aggressive tumor types like IBC
  • Development of novel clinical trials with new biological agents


Wei T. Yang, MDWei T. Yang, MD

Dr. Yang's work focuses upon:

  • Direct imaging of IBC at staging, to include mammography, sonography, imaging-guided biopsy of index breast masses and regional lymph nodes
  • Direct imaging-guided core needle biopsy of the breast for the IBC Registry
  • Direct research evaluation of IBC with MRI and PET/CT
  • Evaluating novel imaging techniques for the evaluation of response to targeted therapy of IBC patients using positron emission mammography (PEM)
  • Evaluating radiologic-pathologic correlation of core needle biopsy samples of the breast for tumor celluairty and facilitation of molecular studies